 Home > Active Ingredient News > Blood System > Leukemia: iFCG chemotherapy regimen for the treatment of chronic lymphocytic leukemia with IGHV mutation and without TP53 mutation

Leukemia: iFCG chemotherapy regimen for the treatment of chronic lymphocytic leukemia with IGHV mutation and without TP53 mutation

 Last Update: 2021-06-21
 Source: Internet
 Author: User

Tags

3 4 water

10 8 performance

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Currently fludarabine (fludarabine), cyclophosphamide (cyclophosphamide) and rituximab (rituximab) (FCR) of chemical immune therapy (CIT) has become the standard treatment strategy for chronic lymphocytic leukemia (CLL) patients

An initial phase II clinical study at the University of Texas MD Anderson Cancer Center (MDACC) showed that the overall response rate of FCR first-line treatment was 95%

The study is a phase II clinical trial for previously untreated CLL patients with IGHV mutations and no del(17p)/TP53 mutations

The patient received three cycles of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG)

Research flow chart

The results showed that a total of 45 patients received treatment, and the median follow-up time for the patients was 41.

Response to treatment

All in all, the results of the study revealed that only 3 cycles of iFCG chemotherapy is an effective time-limited treatment for CLL patients with IGHV mutations and no del(17p)/TP53 mutations

Only 3 cycles of iFCG chemotherapy is an effective time-limited treatment for CLL patients with IGHV mutations and no del(17p)/TP53 mutations

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.